News
FDA approves Samsung/Merck & Co's Herceptin biosimilar
The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.
